Skip to main content
Top
Published in: Pediatric Drugs 6/2014

01-12-2014 | Original Research Article

Optimized Antimicrobial Dosing Strategies: A Survey of Pediatric Hospitals

Authors: Chad A. Knoderer, Kristen R. Nichols, Elaine G. Cox

Published in: Pediatric Drugs | Issue 6/2014

Login to get access

Abstract

Background

Extended-interval aminoglycoside (EIAG) and extended- and continuous-infusion β-lactam (EIBL and CIBL) dosing strategies are increasingly used in adults, but pediatric literature is limited.

Objective

The objective of this study was to describe the use of EIAG, EIBL, and CIBL dosing in pediatric hospitals in the USA.

Study Design, Setting, and Participants

A national survey of children’s hospitals was conducted. A single practitioner from each target hospital was identified through the Children’s Hospital Association. Practice-based survey questions identified whether hospitals utilize EIAG, EIBL, and CIBL dosing.

Main Outcome Measure

The main outcome measure was the percentage utilization of the dosing strategies, with secondary outcomes being the reasons for not using these dosing strategies.

Results

Seventy-seven of 215 identified practitioners (36 %) participated in the survey. EIAG, EIBL, and CIBL dosing were utilized in 63 %, 24 %, and 13 % of responding hospitals, respectively. The most common reasons for not using EIAG were concern regarding lack of efficacy data (56 %) and concern regarding the duration of the drug-free period (41 %). Respondents who did not utilize EIBL cited concern due to lack of pediatric EIBL efficacy data (54 %), the need for more intravenous access (54 %), intravenous medication compatibility issues (39 %), and the time during which the patient is attached to an intravenous infusion (31 %).

Conclusion

This survey of children’s hospitals indicates that EIAG is used in over 50 % of hospitals, but there is some lag in adoption of EIBL and CIBL dosing, both of which are used in fewer than 25 % of hospitals. Additional studies may provide much-needed evidence to increase the utilization of these strategies.
Literature
2.
go back to reference El-Mahallawy HA, El-Wakil M, Moneer MM, Shalaby L. Antibiotic resistance is associated with longer bacteremic episodes and worse outcomes in febrile neutropenic children with cancer. Pediatr Blood Cancer. 2011;57:283–8. doi:10.1002/pbc.22926.PubMedCrossRef El-Mahallawy HA, El-Wakil M, Moneer MM, Shalaby L. Antibiotic resistance is associated with longer bacteremic episodes and worse outcomes in febrile neutropenic children with cancer. Pediatr Blood Cancer. 2011;57:283–8. doi:10.​1002/​pbc.​22926.PubMedCrossRef
4.
go back to reference Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(3):357–63.PubMedCrossRef Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis. 2007;44(3):357–63.PubMedCrossRef
5.
go back to reference Lodise TP Jr, Lomaestro B, Drusano GL. Application of antimicrobial pharmacodynamics concepts into clinical practice: focus on β-lactam antibiotics. Pharmacotherapy. 2006;26:1320–32.PubMedCrossRef Lodise TP Jr, Lomaestro B, Drusano GL. Application of antimicrobial pharmacodynamics concepts into clinical practice: focus on β-lactam antibiotics. Pharmacotherapy. 2006;26:1320–32.PubMedCrossRef
6.
go back to reference Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56:272–82. doi:10.1093/cid/cis857.PubMedCrossRef Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56:272–82. doi:10.​1093/​cid/​cis857.PubMedCrossRef
7.
go back to reference Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with an once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650–5.PubMedCentralPubMedCrossRef Nicolau DP, Freeman CD, Belliveau PP, Nightingale CH, Ross JW, Quintiliani R. Experience with an once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650–5.PubMedCentralPubMedCrossRef
9.
go back to reference Knoderer CA, Everett JA, Buss WF. Clinical issues surrounding once-daily aminoglycoside dosing in children. Pharmacotherapy. 2003;23:44–56.PubMedCrossRef Knoderer CA, Everett JA, Buss WF. Clinical issues surrounding once-daily aminoglycoside dosing in children. Pharmacotherapy. 2003;23:44–56.PubMedCrossRef
10.
11.
go back to reference Knoderer CA, Morris JL, Cox EG. Continuous infusion of nafcillin for sternal osteomyelitis in an infant following cardiac surgery. J Pediatr Pharmacol Ther. 2010;15:49–54.PubMedCentralPubMed Knoderer CA, Morris JL, Cox EG. Continuous infusion of nafcillin for sternal osteomyelitis in an infant following cardiac surgery. J Pediatr Pharmacol Ther. 2010;15:49–54.PubMedCentralPubMed
13.
go back to reference Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for β-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer. 2009;53:379–85. doi:10.1002/pbc.22051.PubMedCrossRef Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for β-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer. 2009;53:379–85. doi:10.​1002/​pbc.​22051.PubMedCrossRef
17.
go back to reference Tamma PD, Turnbull AE, Milstone AM, Hsu AJ, Carroll KC, Cosgrove SE. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia? Clin Infect Dis. 2012;55:799–806. doi:10.1093/cid/cis545.PubMedCentralPubMedCrossRef Tamma PD, Turnbull AE, Milstone AM, Hsu AJ, Carroll KC, Cosgrove SE. Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia? Clin Infect Dis. 2012;55:799–806. doi:10.​1093/​cid/​cis545.PubMedCentralPubMedCrossRef
19.
go back to reference Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an hospital program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.PubMedCrossRef Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an hospital program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159–77.PubMedCrossRef
20.
go back to reference Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.PubMedCrossRef Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.PubMedCrossRef
21.
go back to reference Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin Infect Dis. 1998;26:1–10.PubMedCrossRef Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antimicrobial dosing of mice and men. Clin Infect Dis. 1998;26:1–10.PubMedCrossRef
22.
go back to reference Rubino CM, Bradley JS. Optimizing therapy with antimicrobial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics. Paediatr Drugs. 2007;9:361–9.PubMedCrossRef Rubino CM, Bradley JS. Optimizing therapy with antimicrobial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics. Paediatr Drugs. 2007;9:361–9.PubMedCrossRef
24.
go back to reference DeRyke AC, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antimicrobials utilising pharmacodynamic principles: impact on the development of resistance. Drugs. 2006;66:1–14.PubMedCrossRef DeRyke AC, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antimicrobials utilising pharmacodynamic principles: impact on the development of resistance. Drugs. 2006;66:1–14.PubMedCrossRef
25.
go back to reference Schumock GT, Raber SR, Crawford SY, Naderer OJ, Rodvold KA. National survey of once-daily dosing of aminoglycoside antibiotics. Pharmacotherapy. 1995;15(2):201–9.PubMed Schumock GT, Raber SR, Crawford SY, Naderer OJ, Rodvold KA. National survey of once-daily dosing of aminoglycoside antibiotics. Pharmacotherapy. 1995;15(2):201–9.PubMed
26.
go back to reference Kraus DM, Pai MP, Rodvold KA. Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients. Paediatr Drugs. 2002;4:468–84.CrossRef Kraus DM, Pai MP, Rodvold KA. Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients. Paediatr Drugs. 2002;4:468–84.CrossRef
28.
29.
go back to reference Van der Auwera P, Klastersky J. Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin. Antimicrob Agents Chemother. 1987;31(7):1061–1068.PubMedCentralPubMedCrossRef Van der Auwera P, Klastersky J. Serum bactericidal activity and postantibiotic effect in serum of patients with urinary tract infection receiving high-dose amikacin. Antimicrob Agents Chemother. 1987;31(7):1061–1068.PubMedCentralPubMedCrossRef
Metadata
Title
Optimized Antimicrobial Dosing Strategies: A Survey of Pediatric Hospitals
Authors
Chad A. Knoderer
Kristen R. Nichols
Elaine G. Cox
Publication date
01-12-2014
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 6/2014
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.1007/s40272-014-0093-1

Other articles of this Issue 6/2014

Pediatric Drugs 6/2014 Go to the issue